Related Experiment Videos
[Atherosclerosis and metabolic disease].
1Institute of Medical Science, Health Sciences University of Hokkaido, Sapporo 002-8072.
Rinsho Byori. the Japanese Journal of Clinical Pathology
|March 19, 2004
Summary
Low high-density lipoprotein cholesterol (HDL-C) is a key indicator of cardiovascular disease risk. Addressing dyslipidemia, particularly low HDL-C and high triglycerides, is crucial for preventing atherosclerosis and heart events.
Area of Science:
- Cardiovascular Science
- Metabolic Disorders
- Lipid Metabolism
Background:
- Cholesterol accumulation in atherosclerotic plaques drives atherogenesis.
- Statins effectively reduce low-density lipoprotein cholesterol (LDL-C) and cardiovascular events.
- However, total cholesterol and LDL-C are not always reliable markers for cardiovascular disease risk.
Observation:
- Low high-density lipoprotein cholesterol (HDL-C) is the most predictive marker for cardiovascular disease.
- Low HDL-C often stems from secondary causes, particularly metabolic syndrome and type 2 diabetes.
- Metabolic syndrome and type 2 diabetes are escalating globally, posing significant cardiovascular risks.
Findings:
- Dyslipidemia, characterized by high triglyceride-rich lipoproteins and low HDL-C, accelerates atherosclerosis.
- Small, dense LDL particles and increased postprandial lipemia are key features of dyslipidemia.
- These lipoprotein disturbances collectively enhance the progression of atherosclerosis.
Implications:
- Low HDL-C levels, often secondary to metabolic syndrome, are strongly linked to atherosclerosis.
- Lipid-modifying therapy is likely necessary for many patients to prevent cardiovascular disease.
- Comprehensive management of dyslipidemia is essential for cardiovascular risk reduction.